Cargando…

A single-arm, long-term efficacy and safety study of subcutaneous romiplostim in children with immune thrombocytopenia

Romiplostim is a thrombopoietin (TPO) receptor agonist approved for children and adults with immune thrombocytopenia (ITP) for ≥6 months, recommended as second-line treatment. This phase 3b, single-arm, multicenter study investigated long-term efficacy and safety of romiplostim in children ≥1 to <...

Descripción completa

Detalles Bibliográficos
Autores principales:	Grainger, John, Bussel, James, Tarantino, Michael, Cooper, Nichola, Beam, Donald, Despotovic, Jenny, Maschan, Alexey, Wang, Kejia, Eisen, Melissa, Bowers, Charles
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The American Society of Hematology 2022
Materias:	Regular Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9979726/ https://www.ncbi.nlm.nih.gov/pubmed/35413092 http://dx.doi.org/10.1182/bloodadvances.2021006014

Ejemplares similares

Long-term treatment with romiplostim and treatment-free platelet responses in children with chronic immune thrombocytopenia
por: Tarantino, Michael D., et al.
Publicado: (2019)

Romiplostim use in pregnant women with immune thrombocytopenia
por: Bussel, James B., et al.
Publicado: (2022)

Romiplostim in children with newly diagnosed or persistent primary immune thrombocytopenia
por: Grainger, John D., et al.
Publicado: (2021)

Romiplostim for the Treatment of Immune Thrombocytopenia: Spotlight on Patient Acceptability and Ease of Use
por: Gilbert, Megan M, et al.
Publicado: (2020)

Assessment of romiplostim immunogenicity in pediatric patients in clinical trials and in a global postmarketing registry
por: Bowers, Charles, et al.
Publicado: (2021)

Romiplostim as a treatment for immune thrombocytopenia: a review
por: Chalmers, Sarah, et al.
Publicado: (2015)

Long-Term Use of the Thrombopoietin-Mimetic Romiplostim in Children With Severe Chronic Immune Thrombocytopenia (ITP)
por: Bussel, James B, et al.
Publicado: (2015)

A Review of Romiplostim Mechanism of Action and Clinical Applicability
por: Bussel, James B, et al.
Publicado: (2021)

Safety and efficacy of romiplostim in splenectomized and nonsplenectomized patients with primary immune thrombocytopenia
por: Cines, Douglas B., et al.
Publicado: (2017)

Efficacy and Safety of Biosimilar Romiplostim Versus Innovator Romiplostim in Patients with Chronic Immune Thrombocytopenia
por: Chandrakala, S., et al.
Publicado: (2022)

Correction to: Efficacy and Safety of Biosimilar Romiplostim Versus Innovator Romiplostim in Patients with Chronic Immune Thrombocytopenia
por: Chandrakala, S., et al.
Publicado: (2023)

Romiplostim in adult patients with newly diagnosed or persistent immune thrombocytopenia (ITP) for up to 1 year and in those with chronic ITP for more than 1 year: a subgroup analysis of integrated data from completed romiplostim studies
por: Kuter, David J., et al.
Publicado: (2019)

Romiplostim Treatment of Chemotherapy-Induced Thrombocytopenia
por: Soff, Gerald A., et al.
Publicado: (2019)

Safety and efficacy of self‐administered romiplostim in patients with immune thrombocytopenia: Results of an integrated database of five clinical trials
por: Kuter, David J., et al.
Publicado: (2020)

The role of romiplostim for pediatric patients with immune thrombocytopenia
por: Al-Samkari, Hanny, et al.
Publicado: (2020)

Long-term safety and efficacy of romiplostim for treatment of immune thrombocytopenia
por: Vishnu, Prakash, et al.
Publicado: (2016)

Romiplostim for chemotherapy‐induced thrombocytopenia: Efficacy and safety of extended use
por: Wilkins, Cy R., et al.
Publicado: (2022)

PB2612: UNITED KINGDOM RETROSPECTIVE OBSERVATIONAL STUDY OF ROMIPLOSTIM AND OTHER TREATMENTS IN EARLY IMMUNE THROMBOCYTOPENIA
por: Mcdonald, Vickie, et al.
Publicado: (2023)

Hospitalizations in pediatric patients with immune thrombocytopenia in the United States
por: Tarantino, Michael D., et al.
Publicado: (2016)

Romiplostim as early treatment of immune thrombocytopenia with severe immunodeficiency
por: Palandri, Francesca, et al.
Publicado: (2012)

Role of romiplostim in splenectomized and nonsplenectomized patients with immune thrombocytopenia
por: Perdomo, Jose
Publicado: (2016)

Thrombopoietin mutation in congenital amegakaryocytic thrombocytopenia treatable with romiplostim
por: Pecci, Alessandro, et al.
Publicado: (2017)

Effectiveness and Safety of Romiplostim Among Patients with Newly Diagnosed, Persistent and Chronic Immune Thrombocytopenia in European Clinical Practice
por: Snell Taylor, Sara J., et al.
Publicado: (2021)

Safety and efficacy of romiplostim in children and adolescents with Immune thrombocytopenia: A systematic review
por: de Oliveira, Fernanda Lubiana, et al.
Publicado: (2023)

Myelofibrosis Associated with Romiplostim Treatment in a Patient with Immune Thrombocytopenia
por: Gonzalez, Maria Fernanda, et al.
Publicado: (2012)

Cost Effectiveness of Romiplostim for the Treatment of Chronic Immune Thrombocytopenia in Ireland
por: Lee, Dawn, et al.
Publicado: (2013)

Romiplostim for the Emergency Management of Severe Immune Thrombocytopenia with Intracerebral Hemorrhage
por: Gellens, Romain, et al.
Publicado: (2018)

Treatment of 5 dogs with immune-mediated thrombocytopenia using Romiplostim
por: Kohn, Barbara, et al.
Publicado: (2016)

Romiplostim and Eltrombopag in Immune Thrombocytopenia as a Second-Line Treatment
por: Bidika, Erjola, et al.
Publicado: (2020)

Erratum to: Cost Effectiveness of Romiplostim for the Treatment of Chronic Immune Thrombocytopenia in Ireland
por: Lee, Dawn, et al.
Publicado: (2013)

Erratum to: treatment of 5 dogs with immune-mediated thrombocytopenia using romiplostim
por: Kohn, Barbara, et al.
Publicado: (2016)

Successful Percutaneous Nephrolithotomy in Patients with Immune-Mediated Thrombocytopenia Treated with Romiplostim
por: McCall, Andrew N., et al.
Publicado: (2016)

Changes in bone marrow morphology in adults receiving romiplostim for the treatment of thrombocytopenia associated with primary immune thrombocytopenia
por: Janssens, Ann, et al.
Publicado: (2016)

Reduced corticosteroid use in adult patients with primary immune thrombocytopenia receiving romiplostim
por: Michel, Marc, et al.
Publicado: (2011)

Total remission of severe immune thrombocytopenia after short term treatment with romiplostim
por: Vlachaki, Efthymia, et al.
Publicado: (2011)

New synergistic efficacy of combination of romiplostim and steroid in refractory immune thrombocytopenia patients
por: Yoon, Jun Seok, et al.
Publicado: (2018)

Romiplostim-related myelofibrosis in refractory primary immune thrombocytopenia: A Case report
por: Kim, Hyun-Young, et al.
Publicado: (2019)

Immunomodulation in Primary Immune Thrombocytopenia: A Possible Role of the Fc Fragment of Romiplostim?
por: Schifferli, Alexandra, et al.
Publicado: (2019)

Efficacy and quality of life of Romiplostim in adults and children with immune thrombocytopenia: A review
por: He, Xin, et al.
Publicado: (2022)

Fostamatinib is an effective second‐line therapy in patients with immune thrombocytopenia
por: Boccia, Ralph, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_1vntohmmopusl7jqak9vc1efcd